In male rats, the ability of central insulin to suppress glucose production is impaired by olanzapine, whereas glucose uptake is left intact
Authors:
- 1 November 2017
- journal article
- Published by Canadian Science Publishing in Journal of Psychiatry and Neuroscience
- Vol. 42 (6) , 424-431
Abstract
Background: Insulin receptors are widely expressed in the brain and may represent a crossroad between metabolic and cognitive disorders. Although antipsychotics, such as olanzapine, are the cornerstone treatment for schizophrenia, they are associated with high rates of type 2 diabetes and lack efficacy for illness-related cognitive deficits. Historically, this risk of diabetes was attributed to the weight gain propensity of antipsychotics, but recent work suggests antipsychotics can have weight-independent diabetogenic effects involving unknown brain-mediated mechanisms. Here, we examined whether antipsychotics disrupt central insulin action, hypothesizing that olanzapine would impair the well-established ability of central insulin to supress hepatic glucose production. Methods: Pancreatic euglycemic clamps were used to measure glucose kinetics alongside a central infusion of insulin or vehicle into the third ventricle. Male rats were pretreated with olanzapine or vehicle per our established model of acute olanzapine-induced peripheral insulin resistance. Groups included (central–peripheral) vehicle–vehicle ( n = 11), insulin–vehicle ( n = 10), insulin–olanzapine ( n = 10) and vehicle–olanzapine ( n = 8). Results: There were no differences in peripheral glucose or insulin levels. Unexpectedly, we showed that central insulin increased glucose uptake, and this effect was not perturbed by olanzapine. We replicated suppression of glucose production by insulin (clamp relative to basal: 77.9% ± 13.1%, all p < 0.05), an effect abolished by olanzapine (insulin–olanzapine: 7.7% ± 14%). Limitations: This study used only male rats and an acute dose of olanzapine. Conclusion: To our knowledge, this is the first study suggesting olanzapine may impair central insulin sensing, elucidating a potential mechanism of antipsychotic-induced diabetes and opening avenues of investigation related to domains of schizophrenia psychopathology.Keywords
This publication has 54 references indexed in Scilit:
- Acute Peripheral but Not Central Administration of Olanzapine Induces Hyperglycemia Associated with Hepatic and Extra-Hepatic Insulin ResistancePLOS ONE, 2012
- Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 DiabetesDiabetes Care, 2011
- Central Nervous System Delivery of the Antipsychotic Olanzapine Induces Hepatic Insulin ResistanceDiabetes, 2010
- Hypothalamic AMP-Activated Protein Kinase Regulates Glucose ProductionDiabetes, 2010
- Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysisMolecular Psychiatry, 2010
- Insulin resistance and secretion in vivo: Effects of different antipsychotics in an animal modelSchizophrenia Research, 2009
- Insulin sensitivity, adjusted β-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: A nine-month prospective studyDiabetes & Metabolism, 2008
- Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathwayMolecular Psychiatry, 2008
- Serotonin 2C Receptor Agonists Improve Type 2 Diabetes via Melanocortin-4 Receptor Signaling PathwaysCell Metabolism, 2007
- Glucotoxicity and β-Cell Failure in Type 2 Diabetes MellitusJournal of Pediatric Endocrinology and Metabolism, 2003